Keros Therapeutics Inc (KROS): Rasio rega marang dodolan

Logo korporat perusahaan Keros Pharma (KROS)

A positive image and confidence in the Keros Therapeutics (KROS) pipeline drive a confident growth trajectory. Keros Therapeutics develops therapies for bone and hematological pathologies targeting the orphan market. The financial model relies on investments and partnership payments for innovative developments. The capitalization-to-revenue ratio reflects the asset's valuation dynamics, where 5.00 serves as the current metric level, enabling the timely detection of market anomalies.

KROS: Multiplikator P/S Keros Therapeutics 04.07.2022 - 16.11.2026

Rincian metrik lan analitis perusahaan kerostx.com (KROS)

Analisis umum perusahaan:KROS Keros Therapeutics Inc
Produk dadi Keros Therapeutics

The market values Keros Therapeutics (KROS) through the lens of its diversified biopharmaceutical portfolio's prospects, where the success of clinical trials determines future capitalization. By analyzing the current P/S ratio, an investor can examine the relationship between market value and revenue, making it possible to identify asset overpayment and assess the effectiveness of monetizing scientific developments to ensure the long-term financial sustainability of the business.

Pesaing Keros Therapeutics

VRTX (Vertex Pharmaceuticals Incorporated) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Alnylam ALNY|INSM (Insmed Inc) - Rasio rega marang dodolan|United Therapeutics - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan BMRN (BioMarin Pharmaceutical)|BBIO: Multiplikator P/S|BGM Group Corp - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Cogent Bio|XERS: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan arcturusrx.com (ARCT)|Kapitalisasi marang pendapatan Eton Pharmaceuticals ETON|Multiplikator P/S KMDA (kamada.com)|Multiplikator P/S Fulcrum Therapeutics, Inc. FULC|Abeona Therapeutics - Multiplikator P/S|mereobiopharma.com (MREO) - Kapitalisasi marang pendapatan|Protalix BioTherapeutics Inc. (PLX) - Rasio rega marang pendapatan|PLRX (Pliant Therapeutics Inc) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Applied Therapeutics, Inc.|Rein Therapeutics Inc. (RNTX) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan GELS (Gelteq Limited)|Multiplikator P/S Aytu Therapeutics (AYTU)|Rasio rega marang pendapatan Chemomab Therapeutics Ltd. CMMB|Rasio kapitalisasi pasar marang pendapatan SRXH|Polyrizon Limited - Multiplikator P/S|AEZS (zentaris.com) - Rasio kapitalisasi marang pendapatan|CYTH (Cyclo Therapeutics, Inc.) - Kapitalisasi marang pendapatan|Rega marang dodolan Inozyme Pharma, Inc. (INZY)|RPHM (Reneo Pharmaceuticals) - Multiplikator P/S|COSCIENS Biopharma (CSCI) - Koefisien rega marang pendapatan